Welcome to our dedicated page for Molecular Partners American Depositary Shares news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on Molecular Partners American Depositary Shares stock.
Molecular Partners AG (NASDAQ: MOLN) is a clinical-stage biopharmaceutical company headquartered in Zurich-Schlieren, Switzerland, with an additional office in Concord, Massachusetts. The company specializes in the development of DARPin therapeutics, a new class of custom-built protein drugs designed to tackle complex diseases such as cancer and sight-threatening disorders.
Molecular Partners has a diversified product pipeline focusing primarily on oncology and ophthalmology. In the field of oncology, the firm is advancing multiple DARPin candidates including MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia, which is currently in Phase 1/2a clinical trials. The company's latest innovation, the Switch-DARPin platform, aims to deliver multispecific candidates for conditional activation of targeted immune responses. Another exciting area of development is the Radio-DARPin Therapy (RDT) platform, which uses DARPin technology to enhance tumor uptake and reduce kidney reabsorption of radiopharmaceutical drugs, with lead candidate MP0712 targeting DLL3 in small-cell lung cancer.
On the ophthalmology front, Molecular Partners is developing therapies for retinal diseases, including wet age-related macular degeneration and diabetic macular edema. The firm's dedication to innovation is further evidenced by its strategic collaborations with prominent pharmaceutical companies such as Novartis and Orano Med.
Financially, the company reported CHF 186.9 million in cash and short-term deposits as of year-end 2023 and maintains a strong cash runway well into 2026. Despite a net loss of CHF 62 million for 2023, Molecular Partners continues to invest in its robust pipeline and transformative research initiatives.
Recent news highlights Molecular Partners' presentation at the 42nd Annual J.P. Morgan Healthcare Conference where they provided a business overview and 2024 outlook. The company anticipates significant milestones in 2024, including further clinical data from its lead oncology program MP0533 and progression of its RDT and Switch-DARPin platforms.
For more information, visit www.molecularpartners.com, or follow them on LinkedIn and X @MolecularPrtnrs.
Molecular Partners announced data presentations at SITC 2024 for two programs: a novel CD3 Switch-DARPin T cell engager and MP0317. The CD3 Switch-DARPin platform demonstrated preclinical proof-of-concept for conditional T cell activation in solid tumors, specifically in ovarian cancer models. The technology features an 'on/off' switch mechanism that activates only in the presence of defined tumor antigens.
For MP0317, comprehensive biomarker analyses from its completed Phase 1 trial showed successful CD40 activation in tumor microenvironments across various solid tumors. The data revealed increases in dendritic cells, M1 macrophages, and other immune cells, supporting its tumor-localized approach. The company is now discussing potential investigator-initiated combination trials.
Molecular Partners will present data from its MP0533 and MP0621 programs at the upcoming ASH Annual Meeting. The clinical update on the ongoing MP0533 phase 1/2a dose escalation study shows an acceptable safety profile and initial antileukemic and pharmacodynamic activity. The Switch-DARPin MP0621 demonstrates cKit+ cell killing while reducing off-target effects associated with systemic anti-CD47 blockade. The presentations will take place at the San Diego Convention Center on December 8-9, 2024, featuring data on these DARPin therapeutics for treating AML/MDS and stem cell transplantation conditioning.
Molecular Partners (MOLN) reported its Q3 2024 interim results, highlighting progress across its portfolio. The company's Radio-DARPin candidate MP0712 is preparing for clinical entry in 2025. The company strengthened its agreement with Orano Med to co-develop four 212Pb-based Radio-DARPin candidates. Financial outlook remains strong with CHF 143.6 million in cash as of September 30, 2024, funding operations into 2027. The company expects total operating expenses of CHF 65-70 million in 2024. A recent US offering raised approximately USD 20 million through ADS sales at USD 5.49 per share.
Molecular Partners announced the pricing of an underwritten offering of 3,642,988 American Depositary Shares at $5.49 per ADS, raising approximately $20.0 million in gross proceeds. The offering, expected to close on October 29, 2024, includes participation from new investor HBM Healthcare Investments and existing investors. The company plans to use the proceeds for developing its radiopharmaceutical pipeline (Radio-DARPin Therapeutics), working capital, and general corporate purposes. Leerink Partners and TD Cowen are serving as joint bookrunning managers, with LifeSci Capital as lead manager and Zürcher Kantonalbank as settlement agent.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) and Orano Med presented positive preclinical data for their Radio-DARPin Therapeutic (RDT) candidate MP0712 at the EANM Congress 2024. MP0712, targeting delta-like ligand 3 (DLL3), showed:
- Dose-dependent efficacy with a favorable safety profile
- Attractive tumor to kidney ratios in biodistribution studies
- Picomolar affinity and high specificity for DLL3
The companies plan to initiate first-in-human studies in 2025, pending regulatory clearance. MP0712 demonstrated strong tumor uptake in models with clinically relevant DLL3 expression levels, while maintaining low kidney exposure. The treatment was well-tolerated at clinically relevant dosages and showed strong efficacy compared to a radiolabelled anti-DLL3 antibody.
DLL3 is expressed in >85% of small cell lung cancer tumors and other aggressive neuroendocrine tumors, making it a highly relevant target for radiopharmaceutical therapy.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has strengthened its co-development agreement with Orano Med for 212Pb-based Radio-DARPin Therapeutics. The revised agreement now includes four Radio-DARPin programs, with each company holding commercialization rights to two programs. Molecular Partners retains rights to the first program, MP0712 targeting DLL3, and gains rights to the second nominated Radio-DARPin Candidate.
The companies plan to initiate first-in-human studies for MP0712 in 2025, pending regulatory clearance. Molecular Partners expects no immediate impact on its 2024 financial forecast and maintains its funding guidance into 2027. The company's estimated cash and cash equivalents as of September 30, 2024, are approximately CHF 140 million (unaudited).
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced upcoming poster presentations at the 2024 SITC Annual Meeting. The company will introduce proof-of-concept data for its new CD3 Switch-DARPin, designed to overcome challenges in T cell engagers for solid tumors. Additionally, they will present further analyses from the Phase 1 study of MP0317 in patients with advanced solid tumors.
Two poster presentations are scheduled:
- Title: "Unlocking precision: a next generation multi-specific CD3 Switch-DARPin with enhanced function to tackle the current limitations of T cell engagers in ovarian cancer" (Abstract & Poster Number: 842)
- Title: "Comprehensive biomarker analyses from a Phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic DARPin" (Abstract & Poster Number: 612)
The presentations will take place on November 9, 2024, from 9 am to 8:30 pm CT in Exhibit Halls AB. The posters will be available on Molecular Partners' website after the conference.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced an upcoming presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic (RDT) targeting DLL3 for Small Cell Lung Cancer, at the European Association of Nuclear Medicine (EANM) Congress in Hamburg, Germany, October 19-23, 2024. The presentation, titled "Preclinical Assessment of Lead-212 (²¹²Pb) Radio-DARPin Therapeutic (RDT) Targeting Delta-like Ligand 3 (DLL3) in Small Cell Lung Cancer (SCLC)," will be held on October 22, 2024.
MP0712, co-developed with Orano Med, is Molecular Partners' first RDT candidate. It shows low kidney accumulation and high tumor uptake in preclinical models, leading to strong tumor growth inhibition with a good safety profile in vivo. DLL3 is expressed in >85% of SCLC tumors and other aggressive neuroendocrine tumors, making it a priority target for radiopharmaceutical therapy.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) reported corporate highlights and financials for H1 2024. Key developments include:
- Nomination of MP0712, the first Radio-DARPin Therapy (RDT) candidate targeting DLL3
- Strategic collaboration with Orano Med to co-develop 212Pb-based RDT candidates
- Progression of MP0533 phase 1 dose escalation for AML treatment
- Presentation of preclinical data for Switch-DARPin platform and MP0621
- Positive Phase 1 data for MP0317 presented at ASCO
Financial highlights: CHF 159.1 million cash position as of June 30, 2024, funding operations into 2027. Total operating expenses expected to be CHF 65-75 million in 2024. The company reported an operating loss of CHF 31.8 million and a net loss of CHF 26.4 million for H1 2024.
Molecular Partners (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech firm specializing in DARPin therapeutics, will participate in the 2nd TD Cowen Radiopharmaceutical Innovation Summit on June 17, 2024. Michael Stumpp, Ph.D., EVP and co-founder, will represent the company in a fireside chat at 10:40 a.m. ET (4:40 p.m. CET). The event will be webcast live on Molecular Partners' website and archived for one year.
FAQ
What is the current stock price of Molecular Partners American Depositary Shares (MOLN)?
What is the market cap of Molecular Partners American Depositary Shares (MOLN)?
What is Molecular Partners AG?
What are DARPin therapeutics?
What is the focus of Molecular Partners' product pipeline?
What is the Switch-DARPin platform?
What is the Radio-DARPin Therapy (RDT) platform?
Who are some of Molecular Partners' strategic partners?
What are some key financial highlights for Molecular Partners?
What recent milestones has Molecular Partners achieved?
What is Molecular Partners' lead oncology program?
Where can I find more information about Molecular Partners?
